CD274 and non-small cell lung carcinoma: As the primary approved anti‐tumoral monoclonal antibodies towards PD‐1 by the American Food and Drug Administration (FDA) in 2015, Pembrolizumab (Keytruda) yields superior long‐term survival as a single‐agent intervention compared with platinum‐based chemotherapy arms in advanced NSCLC regardless of PD‐L1 proportion.3